Arie Belldegrun
| Arie S. Belldegrun | |
|---|---|
| Born | 1949 (age 67–68) Israel |
| Residence | Los Angeles, California |
| Citizenship | Israeli and American |
| Alma mater |
Hadassah Medical Center Weizmann Institute of Science |
| Occupation | Chairman, President and CEO of Kite Pharma |
| Years active | 1988-present |
| Net worth |
 US$1 billion (2016)
|
| Spouse(s) | Rebecka Belldegrun |
| Children | 4 |
| Relatives | Poju Zabludowicz (brother-in-law) |
Arie S. Belldegrun (born 1949), MD, FACS, is an Israeli-born American urologic oncologist, businessman, and investor.
Belldegrun was born in Israel. He received his medical degree from the Hadassah Medical Center at Hebrew University of Jerusalem in 1974, and conducted his post-graduate studies at the Weizmann Institute of Science in 1979. He completed his Urologic Surgery residency at Harvard Medical School in 1985, and his Surgical Oncology fellowship at the National Cancer Institute in 1988. He is certified by the American Board of Urology, and is a fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Belldegrun is the Director of the UCLA Institute of Urologic Oncology, Professor of Urology, and Chief of the Division of Urologic Oncology at the David Geffen School of Medicine.
In 1996, Belldegrun established Agensys, an early-stage privately held biotechnology company based in Los Angeles, that is focused on the development of fully human monoclonal antibodies to treat solid tumor cancers in a variety of cancer targets. He served as its founding Chairman of the Board of Directors from 1996 to 2002, and then as a Director until December 2007, when Agensys was acquired by Astellas Pharma in a deal valued at $537 million.
...
Wikipedia